NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BIO

Bio-Rad Laboratories Inc

Jul 03 • 12:53PM ET

251.40

Dollar change +0.75
Percentage change 0.30	%

Healthcare • Medical Devices • USA • NYSE

Peers: DHR TMO ABBV A WAT MTD ILMN BAX

| Held by: IJH VTI VB VBR VXF MDY DFAT IJJ SPMD DFSV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-76.20	Insider Own	32.15%	Shs Outstand	22.56M	Perf Week	3.26%
Market Cap	6.84B	Forward P/E	25.87	EPS next Y	9.72	Insider Trans	-0.03%	Shs Float	18.46M	Perf Month	13.98%
Enterprise Value	6.55B	PEG	-	EPS next Q	1.76	Inst Own	73.71%	Short Float	4.83%	Perf Quarter	2.39%
Income	-2164.11M	P/S	2.69	EPS this Y	-15.54%	Inst Trans	4.53%	Short Ratio	2.28	Perf Half Y	-22.96%
Sales	2.54B	P/B	1.04	EPS next Y	11.59%	ROA	-19.55%	Short Interest	0.89M	Perf YTD	-23.47%
Book/sh	241.72	P/C	4.12	EPS next 5Y	3.03%	ROE	-27.51%	52W High	387.99 -35.20%	Perf Year	-4.76%
Cash/sh	61.06	P/FCF	19.25	EPS past 3/5Y	- -	ROIC	-27.03%	52W Low	211.43 18.90%	Perf 3Y	-49.23%
Dividend Est.	-	EV/EBITDA	12.37	Sales past 3/5Y	-4.24% 2.11%	Gross Margin	54.20%	Volatility	3.65% 3.29%	Perf 5Y	-41.88%
Dividend TTM	-	EV/Sales	2.58	EPS Y/Y TTM	-637.11%	Oper. Margin	13.24%	ATR (14)	7.76	Perf 10Y	67.42%
Dividend Ex-Date	-	Quick Ratio	4.43	Sales Y/Y TTM	-2.46%	Profit Margin	-85.16%	RSI (14)	65.74	Recom	1.78
Dividend Gr. 3/5Y	- -	Current Ratio	5.99	EPS Q/Q	-82.98%	SMA20	6.79%	Beta	0.90	Target Price	314.50
Payout	-	Debt/Eq	0.21	Sales Q/Q	-4.16%	SMA50	6.31%	Rel Volume	0.37	Prev Close	250.65
Employees	7700	LT Debt/Eq	0.20	Earnings	May 01 AMC	SMA200	-14.53%	Avg Volume	390.99K	Price	251.40
IPO	Feb 27, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	40.31% 2.12%	Trades		Volume	78,278	Change	0.30%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-24	Upgrade	Citigroup	Neutral → Buy	$350 → $400
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$340
Jun-03-24	Resumed	Jefferies	Hold	$315
Apr-03-24	Downgrade	Citigroup	Buy → Neutral	$400 → $365
Dec-07-23	Initiated	UBS	Buy	$395
Jun-16-23	Initiated	Wells Fargo	Overweight	$550
Dec-07-22	Initiated	RBC Capital Mkts	Outperform	$565
Aug-25-22	Initiated	Credit Suisse	Outperform	$715
Jan-28-22	Reiterated	Citigroup	Buy	$915 → $750
Jan-08-20	Initiated	Wells Fargo	Overweight	$430
Jan-07-20	Initiated	Citigroup	Buy	$450
Oct-17-18	Initiated	Goldman	Buy	$350
Sep-20-18	Initiated	Morgan Stanley	Equal-Weight	$335
Feb-16-18	Downgrade	CL King	Buy → Neutral
Jul-13-17	Initiated	Wells Fargo	Outperform
Jun-28-17	Upgrade	Deutsche Bank	Hold → Buy	$220 → $255
Jan-18-17	Initiated	Deutsche Bank	Hold	$195
Oct-13-16	Initiated	CL King	Buy
May-06-15	Reiterated	Jefferies	Buy	$150 → $165
Dec-18-09	Initiated	Maxim Group	Buy	$125

Show Previous Ratings

Jun-16-25 08:30AM	Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence? (Zacks)
May-29-25 04:30PM	Bio-Rads Management to Host Investor Meetings During Jefferies Global Healthcare Conference (Business Wire)
May-13-25 09:16AM	Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends (Zacks)
May-12-25 04:30PM	Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference (Business Wire) +7.54%
May-03-25 08:45AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
06:48PM	Loading…
May-02-25 06:48PM	Analyst Report: Bio-Rad Laboratories, Inc. (Morningstar Research)
07:58AM	BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket (Zacks)
May-01-25 10:35PM	Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:40PM	Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates (Zacks)
04:15PM	Bio-Rad Reports First-Quarter 2025 Financial Results (Business Wire)
Apr-29-25 12:59PM	Bio-Rad Laboratories, Inc. (BIO): Among Billionaire Mason Hawkins' Small-Cap Stocks with Huge Upside Potential (Insider Monkey)
Apr-24-25 10:35AM	Ariel Appreciation Fund Q1 2025 Commentary (Seeking Alpha)
10:25AM	Ariel Focus Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-23-25 06:00AM	Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types (GlobeNewswire)
08:09AM	Loading…
Apr-22-25 08:09AM	Does Bio-Rad Laboratories (BIO) Offer a Solid Financial Profile? (Insider Monkey)
Apr-21-25 08:08AM	Should You be Optimistic on Bio-Rad Laboratories's (BIO) Outlook? (Insider Monkey)
Apr-15-25 09:50PM	Parnassus Value Select ETF Q1 2025 Commentary (Seeking Alpha)
04:15PM	Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (Business Wire)
Apr-13-25 12:48PM	Longleaf Partners Global Fund Q1 2025 Commentary (Seeking Alpha)
09:51AM	Longleaf Partners Fund Q1 2025 Commentary (Seeking Alpha)
Apr-10-25 01:29PM	Analyst Report: Bio-Rad Laboratories, Inc. (Morningstar Research) -6.77%
Apr-04-25 08:28PM	Analyst Report: Bio-Rad Laboratories, Inc. (Morningstar Research)
Apr-03-25 09:00AM	Should You Continue to Hold Bio-Rad Stock in Your Portfolio? (Zacks)
Mar-31-25 10:00AM	Bio-Techne Opens New Customer Experience Centre in Germany (Zacks)
09:20AM	Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate (Zacks)
Mar-24-25 04:05PM	Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts (GlobeNewswire)
Mar-21-25 06:34AM	Why Impact Biomedical Inc. (IBO) Surged On Thursday? (InsiderMonkey)
Mar-17-25 05:29PM	Alger Russell Innovation Index Updates for First Quarter 2025 (PR Newswire)
Feb-15-25 10:05AM	Bio-Rad price target lowered to $447 from $477 at RBC Capital (TipRanks)
05:14PM	Loading…
Feb-14-25 05:14PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research) -9.53%
12:07PM	Analyst Report: Bio-Rad Laboratories, Inc. (Morningstar Research)
Feb-13-25 04:20PM	Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results (Business Wire)
04:15PM	Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies (Business Wire)
Feb-11-25 08:46AM	OncoCyte prices $29.1M equity offering (TipRanks)
Feb-10-25 08:30AM	Oncocyte Prices $29.1 Million Equity Offering (GlobeNewswire)
Jan-27-25 05:00PM	Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 (Business Wire)
Jan-08-25 08:15AM	Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests (Business Wire)
Jan-02-25 04:30PM	Bio-Rads Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference (Business Wire)
Nov-24-24 08:05PM	Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory (Insider Monkey)
Nov-21-24 09:00AM	Bio-Rads Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference (Business Wire)
Oct-31-24 11:52AM	Analyst Report: Bio-Rad Laboratories, Inc. (Morningstar Research) +8.35%
09:00AM	Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference (Business Wire)
Oct-30-24 04:15PM	Bio-Rad Reports Third-Quarter 2024 Financial Results (Business Wire)
Oct-14-24 05:30PM	Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 (Business Wire)
Sep-23-24 07:45AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Sep-22-24 06:00AM	Palantir and Dell Are Set to Join the S&P 500 Monday. Here's What That Means. (Investopedia)
Sep-19-24 04:20PM	What Friday's Triple-Witching Means For You (Investopedia)
Sep-09-24 10:56AM	Palantir and Dell Will Join S&P 500 What You Need To Know (Investopedia)
Sep-06-24 06:43PM	Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Aug-28-24 05:25PM	S&P 500 Gains and Losses Today: Supermicro Stock Plunges on Annual Report Delay (Investopedia)
Aug-22-24 04:30PM	Bio-Rads Management to Participate in Fireside Chat During Wells Fargos 2024 Healthcare Conference (Business Wire)
Aug-20-24 08:30AM	Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer (Business Wire)
Aug-01-24 04:15PM	Bio-Rad Reports Second-Quarter 2024 Financial Results (Business Wire)
Jul-17-24 04:30PM	Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024 (Business Wire) -5.77%
Jun-21-24 08:30AM	Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now? (Zacks)
Jun-14-24 04:35AM	Is Bio-Rad Laboratories (BIO) a Lucrative Investment? (Insider Monkey)
Jun-06-24 11:31AM	Why Is Bio-Rad (BIO) Up 7.8% Since Last Earnings Report? (Zacks)
May-30-24 09:00AM	Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group (Business Wire)
May-23-24 04:15PM	Bio-Rads Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference (Business Wire)
May-08-24 01:52PM	Analyst Report: Bio-Rad Laboratories, Inc. (Morningstar Research)
12:17PM	Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down (Zacks)
09:03AM	Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 05:30PM	Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates (Zacks)
04:15PM	Bio-Rad Reports First-Quarter 2024 Financial Results (Business Wire)
May-04-24 12:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire)
May-01-24 09:00AM	Bio-Rads Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference (Business Wire)
Apr-30-24 10:00AM	Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-26-24 08:30AM	Bio-Rad Announces Life Science Group Management Changes (Business Wire)
Apr-18-24 10:03AM	Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits? (Zacks)
09:00AM	Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (Business Wire)
Apr-16-24 10:56AM	Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition (Zacks)
Apr-11-24 05:30PM	Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay (GlobeNewswire) -5.81%
Apr-10-24 04:15PM	Bio-Rads Chief Operating Officer Andrew Last to Retire (Business Wire)
Mar-31-24 04:34PM	25 Countries with Highest Malaria Death Rates (Insider Monkey)
Mar-20-24 08:30AM	Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer (Business Wire)
Mar-12-24 08:27AM	Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition (Zacks)
Feb-24-24 03:25PM	Billionaires Mario Gabelli and Mason Hawkins Love These 5 Stocks (Insider Monkey)
Feb-22-24 04:30PM	Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day (Business Wire)
Feb-15-24 04:15PM	Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-05-24 11:32AM	Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits? (Zacks)
Jan-24-24 05:00PM	Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 (Business Wire)
Jan-02-24 04:15PM	Bio-Rads Management to Host Investor Meetings at J.P. Morgans 42nd Annual Healthcare Conference (Business Wire)
Dec-12-23 12:42PM	5 Beaten Down Stocks Billionaires Are Crazy About (Insider Monkey)
Oct-27-23 11:21AM	Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.15%
Oct-26-23 04:15PM	Bio-Rad Reports Third-Quarter 2023 Financial Results (Business Wire)
Oct-05-23 08:30AM	Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 (Business Wire)
Sep-19-23 05:43AM	New Strong Sell Stocks for September 19th (Zacks)
Aug-28-23 04:15PM	Bio-Rad to Participate in Fireside Chat During Wells Fargos 2023 Healthcare Conference (Business Wire)
Aug-03-23 04:15PM	Bio-Rad Reports Second-Quarter 2023 Financial Results (Business Wire)
Jul-26-23 04:15PM	Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement (Business Wire)
Jul-20-23 04:30PM	Bio-Rad Announces New Share Repurchase Program (Business Wire)
Jul-10-23 04:30PM	Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023 (Business Wire)
09:00AM	Bio-Rad Publishes Corporate Sustainability Report for 2022 (Business Wire)
Jun-26-23 04:00PM	Wells Fargo Predicts up to 125% Rally for These 2 Stocks Heres Why They Have Solid Upside (TipRanks)
Jun-21-23 08:00PM	BIO: Lowering target price to $385.00 (Argus Research)
Jun-01-23 08:00AM	Bio-Rad to Present Company Overview at Jefferies Healthcare Conference (Business Wire)
May-08-23 08:00AM	Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-04-23 04:15PM	Bio-Rad Reports First-Quarter 2023 Financial Results (Business Wire) -16.72%

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lakkaraju Roop Kalyan	EVP, Chief Financial Officer	Apr 24 '25	Option Exercise	0.00	1,077	0	1,231	Apr 25 06:07 PM
ENLOE COURTNEY C	EVP, General Counsel & Sec	Apr 24 '25	Option Exercise	0.00	186	0	196	Apr 25 06:06 PM
PINKSTON ARNOLD A	Director	Apr 22 '25	Option Exercise	0.00	308	0	308	Apr 24 05:15 PM
PEI MELINDA LITHERLAND	Director	Apr 22 '25	Option Exercise	0.00	308	0	308	Apr 24 05:14 PM
HINCKLEY GREGORY K	Director	Apr 22 '25	Option Exercise	0.00	308	0	308	Apr 24 05:14 PM
EDWARDS JEFFREY L	Director	Apr 22 '25	Option Exercise	0.00	308	0	308	Apr 24 05:13 PM
Crowley Michael	EVP, GBL Commercial Operations	Mar 14 '25	Option Exercise	159.32	3,000	477,960	11,171	Mar 18 04:36 PM
Crowley Michael	EVP, GBL Commercial Operations	Mar 14 '25	Sale	247.06	3,000	741,184	8,171	Mar 18 04:36 PM
Crowley Michael	Officer	Mar 13 '25	Proposed Sale	260.00	3,000	780,000		Mar 13 05:17 PM
Alles Institute for Medical Re	Director	Mar 11 '25	Proposed Sale	247.66	410	101,540		Mar 11 12:36 PM
Last Andrew J.	Officer	Nov 06 '24	Proposed Sale	373.64	3,000	1,120,934		Nov 06 06:26 PM
EVRAN SEDAT	EVP, Global Supply Chain	Oct 20 '24	Option Exercise	0.00	1,044	0	1,188	Oct 22 04:30 PM
Last Andrew J.	Officer	Sep 12 '24	Proposed Sale	321.57	1,600	514,505		Sep 12 06:22 PM
Last Andrew J.	EVP, Chief Operating Officer	Sep 06 '24	Option Exercise	299.24	3,000	897,720	10,559	Sep 10 02:05 PM
Last Andrew J.	EVP, Chief Operating Officer	Sep 06 '24	Sale	329.94	3,000	989,815	7,559	Sep 10 02:05 PM
Last Andrew J.	Officer	Sep 06 '24	Proposed Sale	329.94	3,000	989,815		Sep 06 04:16 PM
Crowley Michael	EVP, GBL Commercial Operations	Sep 03 '24	Option Exercise	0.00	557	0	8,454	Sep 05 09:36 AM
Crowley Michael	EVP, GBL Commercial Operations	Sep 02 '24	Option Exercise	0.00	434	0	8,052	Sep 05 09:36 AM
Crowley Michael	EVP, GBL Commercial Operations	Sep 01 '24	Option Exercise	0.00	1,676	0	7,763	Sep 05 09:36 AM
SCHWARTZ NORMAN D	Chairman, President, and CEO	Sep 03 '24	Option Exercise	0.00	2,320	0	439,479	Sep 04 08:35 PM
SCHWARTZ NORMAN D	Chairman, President, and CEO	Sep 02 '24	Option Exercise	0.00	1,805	0	438,124	Sep 04 08:35 PM
SCHWARTZ NORMAN D	Chairman, President, and CEO	Sep 01 '24	Option Exercise	0.00	6,352	0	436,864	Sep 04 08:35 PM
COREY COLLEEN	EVP, Global Human Resources	Sep 03 '24	Option Exercise	0.00	495	0	18,656	Sep 04 08:25 PM
COREY COLLEEN	EVP, Global Human Resources	Sep 02 '24	Option Exercise	0.00	361	0	18,290	Sep 04 08:25 PM
COREY COLLEEN	EVP, Global Human Resources	Sep 01 '24	Option Exercise	0.00	1,100	0	18,020	Sep 04 08:25 PM
BARRY JAMES	EVP, President, LSG	Sep 03 '24	Option Exercise	0.00	217	0	848	Sep 04 08:24 PM
BARRY JAMES	EVP, President, LSG	Sep 02 '24	Option Exercise	0.00	265	0	726	Sep 04 08:24 PM
BARRY JAMES	EVP, President, LSG	Sep 01 '24	Option Exercise	0.00	600	0	525	Sep 04 08:24 PM
BARRY JAMES	EVP, President, LSG	Sep 04 '24	Sale	330.49	623	205,898	147	Sep 04 08:24 PM
Last Andrew J.	EVP, Chief Operating Officer	Sep 02 '24	Option Exercise	0.00	903	0	8,017	Sep 04 08:19 PM
Last Andrew J.	EVP, Chief Operating Officer	Sep 01 '24	Option Exercise	0.00	2,752	0	7,435	Sep 04 08:19 PM
Allison Schwartz	Director	Sep 03 '24	Option Exercise	0.00	56	0	1,332	Sep 04 08:08 PM
Allison Schwartz	Director	Sep 02 '24	Option Exercise	0.00	44	0	1,297	Sep 04 08:08 PM
Allison Schwartz	Director	Sep 01 '24	Option Exercise	0.00	147	0	1,268	Sep 04 08:08 PM
BARRY JAMES	Officer	Sep 04 '24	Proposed Sale	330.49	623	205,898		Sep 04 06:24 PM
Alles Institute for Medical Re	Director	Aug 27 '24	Proposed Sale	311.34	990	308,225		Aug 27 12:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIO

Bio-Rad Laboratories Inc

Upgrade your FINVIZ experience